about
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomyEffects of resveratrol in experimental and clinical non-alcoholic fatty liver diseasePlasma levels of OLFM4 in normals and patients with gastrointestinal cancerPlacebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.Effect of resveratrol on experimental non-alcoholic steatohepatitis.Smarcc1 expression: a significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure.Snail1 is over-expressed in prostate cancer.Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience.Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment.Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis.Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease.Prostate cancer: to scan or not to scan for lymph node involvement?[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]Urea cycle dysregulation in non-alcoholic fatty liver disease[Treatment of non-alcoholic fatty liver disease]Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion
P50
Q28235697-359D1200-BE81-476C-A670-D331C256162BQ33563877-235AD46E-247F-42F9-A841-3B7D90CCA4E9Q36394711-D493C2E0-B7C4-4FD8-9C3A-2367545F61A5Q40122113-5706C1EF-90CD-4EE1-A355-74562E09C531Q42702171-F2D5D5EE-B01D-4091-BF49-DFC13BC13D45Q43813617-024C32BF-1ECA-4596-86BC-7CC4F29B12FFQ44307471-3DDF530E-B9E6-48D1-A52A-67203C0A2738Q46636982-D92771E5-D571-495E-8292-414E061D471FQ48141180-67C73478-5A0D-4455-9464-8D1150E49A79Q49334398-5C8157E9-8969-4315-9ECC-B60A5E4FD419Q53758887-3DBCC8E1-13C5-49F8-9B61-85BE3F889C2EQ54095552-65FF0AB4-60B9-4765-840A-8B59FD9FF7FEQ81244801-47F9ED00-DB5E-4371-A5B8-8B63085994DCQ83472650-5D6FB3DB-06F4-4403-BB61-83CFAB87F540Q89453037-BDF93757-F1F1-4F16-89DC-D8CCD4F7748BQ90668828-7875060E-7E62-47AF-AF3E-AD1CE2B4254EQ92447735-F6F8A965-F335-4145-8A62-DA91A63B9867
P50
description
researcher ORCID ID = 0000-0002-3474-0379
@en
wetenschapper
@nl
name
Sara Heebøll
@ast
Sara Heebøll
@en
Sara Heebøll
@es
Sara Heebøll
@nl
type
label
Sara Heebøll
@ast
Sara Heebøll
@en
Sara Heebøll
@es
Sara Heebøll
@nl
prefLabel
Sara Heebøll
@ast
Sara Heebøll
@en
Sara Heebøll
@es
Sara Heebøll
@nl
P106
P1153
23027790500
P21
P31
P496
0000-0002-3474-0379